Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that its CFO, Elaine Sun, will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 1:20 p.m. ET. An audio-only link for the presentation will be available in the "Investors" section of the Halozyme website, with a recording accessible for six months post-event. Halozyme specializes in biopharmaceutical solutions to enhance patient experiences and outcomes, leveraging its ENHANZE® technology to reduce treatment times significantly. The company's partnerships with major pharmaceutical firms play a key role in its growth.
- None.
- None.
SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun, senior vice president and chief financial officer, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 1:20 p.m. Eastern Time / 10:20 a.m. Pacific Time.
An audio-only direct link of the presentation can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 6 months following the event. To access the link, please visit Halozyme's website approximately 10 minutes prior to the presentation to register and download any necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has touched more than 500,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including AbbVie, Alexion, argenx, Baxalta, Bristol-Myers Squibb, Horizon, Janssen, Lilly, Pfizer, Roche and ViiV Healthcare. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit Halozyme.com and connect with us on LinkedIn and Twitter.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-301378066.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme present at the Cantor Virtual Global Healthcare Conference?
Who will represent Halozyme at the conference?
How can I access Halozyme's presentation?
What is the ENHANZE® technology developed by Halozyme?
How does Halozyme generate revenue?
